




# Chloroquine

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > For curative treatment

ATC codes: **P01BA01**

|                          |   |
|--------------------------|---|
| Indication               | Malaria due to Plasmodium falciparum <span>ICD11 code: <b>1F40</b></span>   |
| INN                      | Chloroquine   |
| Medicine type            | Chemical agent  |
| List type                | Core  |
| Formulations             | Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)<br>Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)<br>Oral > Solid: 150 mg tablet (as phosphate or sulfate) ; 100 mg tablet (as phosphate or sulfate) |
| EML status history       | First added in 1977 ( <b>TRS 615</b> )<br>Changed in 1979 ( <b>TRS 641</b> )<br>Changed in 1982 ( <b>TRS 685</b> )<br>Changed in 1995 ( <b>TRS 867</b> )<br>Changed in 2003 ( <b>TRS 920</b> )<br>Removed in 2007 ( <b>TRS 946</b> )  |
| Sex                      | All   |
| Age                      | Adolescents and adults  |
| Therapeutic alternatives | The recommendation is for this specific medicine  |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .    |
| Wikipedia                | <a href="#">Chloroquine</a>    |
| DrugBank                 | <a href="#">Chloroquine</a>    |

## Summary of evidence and Expert Committee recommendations

Chloroquine was maintained on the core list, but for use only in the treatment of *P. vivax*, *P. ovale* and *P. malariae* infections.

